XEN445
Modify Date: 2025-08-20 18:32:26
XEN445 structure
|
Common Name | XEN445 | ||
|---|---|---|---|---|
| CAS Number | 1515856-92-4 | Molecular Weight | 366.334 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 490.9±45.0 °C at 760 mmHg | |
| Molecular Formula | C18H17F3N2O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 250.7±28.7 °C | |
Use of XEN445XEN445 is a potent and selective EL inhibitor(IC50=0.237 uM), that showed good ADME and PK properties, and demonstrated in vivo efficacy in raising plasma HDLc concentrations in mice.IC50 value: 0.237 uM [1]Target: Endothelial lipase inhibitorXEN445 can be readily prepared in good yield from commercial available chemicals, which was selected for further evaluation of this series of EL inhibitors. After a 30 min preincubation of EL-expressing HEK cells with XEN445, the IC50 value for XEN445 of 0.25 lM was obtained. This value was very similar to that determined in the cell-free assay. Wild-type mice were orally dosed with XEN445 at 30 mg/kg b.i.d. for 3 days and blood was taken on the morning of day 4, 16 h post final dose. At termination, the average plasma levels of XEN445 was 9.9 lM and the drug caused an 18% and 16% increase in total plasma cholesterol and HDLc, respectively. |
| Name | 2-[(3S)-3-(2-Pyridinylmethoxy)-1-pyrrolidinyl]-5-(trifluoromethyl)benzoic acid |
|---|---|
| Synonym | More Synonyms |
| Description | XEN445 is a potent and selective EL inhibitor(IC50=0.237 uM), that showed good ADME and PK properties, and demonstrated in vivo efficacy in raising plasma HDLc concentrations in mice.IC50 value: 0.237 uM [1]Target: Endothelial lipase inhibitorXEN445 can be readily prepared in good yield from commercial available chemicals, which was selected for further evaluation of this series of EL inhibitors. After a 30 min preincubation of EL-expressing HEK cells with XEN445, the IC50 value for XEN445 of 0.25 lM was obtained. This value was very similar to that determined in the cell-free assay. Wild-type mice were orally dosed with XEN445 at 30 mg/kg b.i.d. for 3 days and blood was taken on the morning of day 4, 16 h post final dose. At termination, the average plasma levels of XEN445 was 9.9 lM and the drug caused an 18% and 16% increase in total plasma cholesterol and HDLc, respectively. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 490.9±45.0 °C at 760 mmHg |
| Molecular Formula | C18H17F3N2O3 |
| Molecular Weight | 366.334 |
| Flash Point | 250.7±28.7 °C |
| Exact Mass | 366.119141 |
| LogP | 3.30 |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C |
| Index of Refraction | 1.583 |
| InChIKey | NBGRERFNOKZQLO-AWEZNQCLSA-N |
| SMILES | O=C(O)c1cc(C(F)(F)F)ccc1N1CCC(OCc2ccccn2)C1 |
| Storage condition | -20℃ |
| RIDADR | NONH for all modes of transport |
|---|
| Benzoic acid, 2-[(3S)-3-(2-pyridinylmethoxy)-1-pyrrolidinyl]-5-(trifluoromethyl)- |
| 2-[(3S)-3-(2-Pyridinylmethoxy)-1-pyrrolidinyl]-5-(trifluoromethyl)benzoic acid |
| (S)-2-(3-(PYRIDIN-2-YLMETHOXY)PYRROLIDIN-1-YL)-5-(TRIFLUOROMETHYL)BENZOIC ACID. HCL |
| XEN-445 |
| XEN445 |